13F Pro quality score
Rank #2,914 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Alaunos Therapeutics, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $5.0K | $-4.2M | — |
| FY 2024 | 10-K | $10.0K | $-4.7M | — |
| FY 2023 | 10-K | $5.0K | $-4.7M | — |
| FY 2022 | 10-K | $2.9M | $-37.7M | — |
| FY 2021 | 10-K | $398.0K | $-78.8M | — |
| FY 2018 | 10-K | $146.0K | $-53.1M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Alaunos Therapeutics, Inc. (TCRT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TCRT at 6.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,914 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of TCRT by reported 13-F value include BlackRock, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. TCRT trades on the Nasdaq exchange and files with the SEC under CIK 1107421. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TCRT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alaunos Therapeutics, Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1107421 →